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Abstract
Background:  Digitoxin induces apoptosis in different human malignant cell lines in vitro. In this
paper we investigated if patients taking digitoxin for cardiac disease have a different cancer
incidence compared to the general population.
Methods:  Computer stored data on digitoxin concentrations in plasma from 9271 patients with
cardiac disease were used to define a user population. Age and sex matched controls from the
Norwegian Cancer Registry were used to calculate the number of expected cancer cases.
Results:  The population on digitoxin showed a higher incidence of cancer compared to the
control population. However, an additional analysis showed that the population on digitoxin had a
general increased risk of cancer already, before the start on digitoxin. Leukemia/lymphoma were
the cancer types which stood out with the highest risk in the digitoxin population before starting
on digitoxin. This indicates that yet unknown risk factors exist for cardiovascular disease and
lymphoproliferative cancer.
An internal dose-response analysis revealed a relationship between high plasma concentration of
digitoxin and a lower risk for leukemia/lymphoma and for cancer of the kidney/urinary tract.
Conclusion:  Morbidity and mortality are high in the population on digitoxin, due to high age and
cardiac disease.These factors disturb efforts to isolate an eventual anticancer effect of digitoxin in
this setting. Still, the results may indicate an anticancer effect of digitoxin for leukemia/lymphoma
and kidney/urinary tract cancers. Prospective clinical cancer trials have to be done to find out if
digitoxin and other cardiac glycosides are useful as anticancer agents.
Background
Cardiac glycosides have been used in the treatment of
cardiac disease for more than 200 years. In most West-
ern countries digitoxin has been replaced by digoxin and
other drugs. Digitoxin is still today the most common
cardiac glycoside prescribed in Norway [1]. Digoxin has
a shorter elimination half life and is often regarded easier
to dosage than digitoxin. However, more attention is
again paid to digitoxin as a valuable cardiac drug, espe-
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cially for the eldery, and perhaps its use will increase in
the future [2].
Cardiac glycosides also have well known antiproliferative
effects on tumor cells [3–5]. Some cardiac glycosides
have been evaluated in short term animal models. The
conclusion from these experiments is that very high dos-
es, probably toxic, would be needed for obtaining anti-
cancer effects in humans [6]. In contrast, we have
previously found that non toxic concentrations of digi-
toxin and digoxin inhibits growth and induce apoptosis
in different human malignant cell lines, whereas highly
proliferating normal cells were not affected [7–9]. The
capability of cardiac glycosides to induce apoptosis has
recently been confirmed in other studies [10,11]. There is
a great difference in susceptibility for cardiac glycosides
in different species indicating that one can not extrapo-
late the results from animal models into humans [4].
In our in vitro experiments the apoptosis-inducing effect
was more potent for digitoxin than for digoxin, and for
digitoxin there was a dose response pattern; the higher
concentration the more apoptosis. Another recent report
on the anticancer effects of different cardiac glycosides
on tumor cell lines also confirms that digitoxin seems
more potent than digoxin [12].
As previous studies on cancer risk in patients on digitalis
more or less exclusively concern digoxin [13–16] we have
studied the possible anticancer effect of digitoxin in pa-
tients with cardiac disease. Thus, we wanted to examine
if the strong anticancer effects detected in vitro were ev-
ident in vivo in a patient population on the drug for car-
diac disease.
Material and Methods
In Norway patients on digitoxin usually have their plas-
ma concentration checked shortly after the initiation of
the treatment. The basis of the study is all cardiac pa-
tients (n = 9271, 5026 women and 4245 men) who had
their first digitoxin concentration measurement carried
out in the period 1986–96 at the University Hospital of
Trondheim. The settlement is very stable for these pa-
tients, so our figures are not influenced by that patients
have had their plasma digitoxin measured in any other
hospital. The digitoxin concentrations were measured by
a radio-immunoassay method (Coat-A-Count Digitoxin,
Diagnostic Products Corporation, Los Angeles, USA).
The reference range for therapeutic plasma digitoxin
concentration at our laboratory is 15–33 nmol/1 (12–25
ng/ml). The mean age for the total digitoxin population
was 75.8 years (1 SD = 10.2), for men 73.3 years (1 SD =
10.3) and women 78.0 years (1 SD = 9.5). After approval
of the Norwegian Data Inspectorate, the regional ethical
committee and the Norwegian Health Inspectorate, the
digitoxin data were linked to individual data on cancer in
the population based Norwegian Cancer Registry.
To study the association between digitoxin use and can-
cer, three different approaches were used.
Firstly, a prospective design was chosen. All the digitoxin
users with no prior cancer diagnosis formed a basis co-
hort from the time they have their first digitoxin plasma
concentration measurement carried out. This cohort was
followed for the occurrence of cancer until the subjects
died or up to December 31, 1996. The expected number
of cases for each type of cancer was calculated by apply-
ing the national cancer rates matched exactly on year of
birth, age and sex. The standardized incidence ration
(SIR) was calculated for all types of cancers having more
than 30 expected cases. The 95% confidence intervals
were estimated on the basis of the Poisson-distribution.
The second approach was a retrospective design based
on persons who were identified in the laboratory data-
base as digitoxin users. For each becoming digitoxin user
one control person was randomly picked out from the
general population. These controls were matched by
birth date and gender and they should be alive at the time
when the corresponding becoming digitoxin user started
on digitoxin.These two groups were compared with re-
spect to having a cancer diagnosis during the period of
observation and the Odds ratio of cancer cases before
start on digitoxin was used as a risk estimate. The 95 %
confidence intervals were estimated on the basis of the
Mantel-Haenzel chi-square estimation. As the control
persons are randomly picked out from the general popu-
lation matched by birthday and gender, we do not know
anything about eventual drug use in the controls. Thus,
some of the controls might use digitoxin and other drugs.
However, the frequency of digitalis users in the general
population is so low that it is not likely to corrupt our fig-
ures significantly.
The third approach was a prospective internal dose-re-
sponse on the cohort on digitoxin users where the risk of
cancer was studied by different levels of digitoxin plasma
concentration at first measurement divided in tertiles
and a Cox regression analysis was carried out. For the
trend analysis the continuous values for the digitoxin
variables was used.The the lowest plasma digitoxin con-
centration (< 16 ng/ml) was set as reference.
Results
Table 1 demonstrates a general higher cancer incidence
in the population on digitoxin compared to what is ex-
pected in the general population. However, it is not clear
whether the population of digitoxin users differ from the
general population in cancer risk already before start onBMC Cancer 2001, 1:11 http://www.biomedcentral.com/1471-2407/1/11
the drug. Table 2 presents the results of the second ap-
proach where we wanted to examine if the persons on
digitoxin had an increased risk of cancer already before
they had started to take the drug. Here the actual number
of cancer cases in the population of "becoming digitoxin
users" is compared with the number of cases in the age
and sex matched control group (presented as Odds ratio
(OR) for each type of cancer). Thus, more cancer cases
were seen in the group to become digitoxin users (OR >
1.00) except for melanoma and other skin cancers. Lym-
phoma and leukemia are presented as a single group in
the tables due to the close relationship between them. In
the prospective part of the study (as presented in Table 1)
for leukemia alone SIR was 1.39 (95% CI: 0.95–1.97) (31
observed versus 22.3 expected). In the comparison be-
tween becoming digitoxin users and the controls (as pre-
sented in Table 2), the Odds ratio for leukemia was 1.95
(95% CI: 1.42–2.67). The internal dose-response analy-
sis is shown in Table 3. For most types of cancer we could
not find any association, neither for all types of cancer
combined. However, a test for trend by level of digitoxin
concentration indicated a trend toward a protective ef-
fects of high digitoxin levels for the lymphoma/leukemia
group (p = 0.008) and for kidney/urinary organ cancers
(p = 0.05).
Discussion
The intention with the present study was to investigate
whether use of digitoxin induces any changes in the inci-
dence of cancer. One strength in our material is that we
Table 1: Observed and expected cancer cases among digitoxin users.
ICD-10 Site Sex Observed Expected SIR (95 % CI)
C50 Breast F 57 45.7 1.25(0.95, 1.62)
C61 Prostate M 108 86.7 1.25(1.03, 1.50)
C18–21 Colo-rectal M+F 127 98.5 1.29(1.06, 1.51)
C32–34 Lung M+F 63 46.4 1.35(1.04, 1.74)
C64,C65,C67,C68 Kidney, urinary M+F 59 51.8 1.14(0.87, 1.47)
C43.C44 Melanoma, other skin M+F 61 49.7 1.23(0.94, 1.58)
C81–C85,C88–C92 Leukemia/Lymphoma M+F 53 37.5 1.41 (1.06, 1.85)
C00–C97 All sites M+F 641 502.8 1.27(1.18, 1.37)
Observed and expected cancer cases amoung digitoxin users, and standardized incidence ratio (SIR) presented for all types of cancers having more 
than 30 expected cases. The cancer types are divided in the groups according to ICD-10 (International Classification of Disease).Observed=cancer 
cases in the population on digitoxin after start on the drug,no lag time applied. Expected=expected cancer cases calculated by applying the national 
cancer rates matched exactly on year of birth,age and sex.
Table 2: Number of cancer cases among subjects that subsequently became digitoxin users.
ICD-10 Site Sex Digitoxin group Control group Odds Ratio (95% 
CI)
C50 Breast F 275 232 1.19(1.11, 1.28)
C61 Prostate M 370 296 1.25(1.08, 1.45)
C18–21 Colo-rectal M+F 430 325 1.32(1.15, 1.52)
C32–34 Lung M+F 163 112 1.46(1.15, 1.86)
C64,C65,C67,C68 Kidney, urinary M+F 201 180 1.06(0.95, 1.17)
C43.C44 Melanoma, other skin M+F 154 191 0.81 (0.66, 0.99)
C81–C85,C88– Leukemia/Lymphoma M+F 198 117 1.69(1.35,2.11)
C92
C00–C97 All sites M+F 2435 2017 1.21 (1.15, 1.28)
Number of cancer cases among subjects that subsequently became digitoxin users,and among matched controls.Digitoxin group=the cancer cases 
among the 9271 patients constituting the database just before the start on digitoxin medication. Control group=for each subject in the digitoxin 
group one control was randomly picked out from the general population. These controls were matched on birthday and gender and should be alive 
at the time when the corresponding digitoxin user started on digitoxin.BMC Cancer 2001, 1:11 http://www.biomedcentral.com/1471-2407/1/11
use plasma concentration measurements for defining the
digitoxin using population. In previous studies drug use
has been estimated by employing dispensing data or
questionnaires about drug use [13–15]. These methods
are less reliable than measuring plasma drug concentra-
tion, as neither completely account for variations in re-
call biases, complicance, nor for the existing inter-
individual pharmacokinetic variability.
As mentioned earlier, digoxin and other cardiac glyco-
sides are more commonly used in many countries and
the use in the earlier studies is usually not specified to
just one drug, but to the digitalis group of prescription
drugs [13–15,17]. We found a general higher incidence of
cancer among the patients on digitoxin. This is in agree-
ment with the earlier published studies [13–15,17]. These
studies have just presented figures on cancer incidence
after commencement on the drug, as we have done in the
prospective part of our study (Table 1). The general high-
er incidence of cancer in the cardiac population on digi-
toxin thus prompted us to perform the analysis
presented in Table 2. These figures show that the popu-
lation to become digitoxin using has an increased risk of
having cancer also before starting on digitoxin medica-
tion. Thus there exist risk factors associated with both
cancer and cardiovascular disease. For some types of
cancer this association may be explained by food habits,
smoking and other factors. Intake of food rich in antioxi-
dants and a favorable composition of carbohydrates, fats
and proteins as well as vitamines and minerals may re-
duce morbidity in both cardiovascular disease and can-
cer [18]. Smoking is an evident risk factor for both lung
cancer and cardiovascular disease.
Surprisingly, the leukemia/lymphoma group shows the
highest Odds ratio and melanoma/other skin cancers the
lowest (Table 2). Excessive exposition to sunlight shows
a positive correlation with the development of skin can-
cer [19]. The lower Odds ratio (OR) for the development
of skin cancer could hypothetically be explained by a dif-
ferent life style, as people who will develop cardiac dis-
ease and subsequent become digitoxin users may be
more in house and therefore not exposed to sunlight to
the same extent. However, the increased SIR value for
skin cancer (Table 1) is more difficult to explain.
The high risk of lymphoproliferative cancers before start
on digitoxin is intriguing (Table 2). Microbiological
agents are associated with some types of cardiovascular
disease and also for the development of cancer, but
whether mutual agents exists are unclear [20,21]. Our
ratios are well in agreement with a previous study focus-
ing on drug use and other factors preceding non Hodgkin
lymphoma [15]. This substantiates that yet unknown
common risk factors exist for the development of cardio-
vascular disease and lymphoproliferative cancer. A pos-
sible protective effect of digitoxin here is indicated by a
dose response pattern in the internal analysis. In addi-
tion, human leukemic cell lines in the form of Jurkat (T-
cell leukemia) and Daudi (B-cell leukemia) are among
the most susceptible for apoptosis induction by digitoxin
treatment in vitro [8]. This further support that the SIR
– OR ratio (1.39/1.95) for leukemia of 0.71 may indicate
an anticancer effect.
It is evident that tracking anticancer effects in a popula-
tion of patients with serious cardiac disease is hampered
by several confounding factors. The mean time of digi-
toxin use before the cancer diagnosis is just about 3 years
in our material. In general studies on cancer incidence in
relation to drug use may be biased by that the cancer, be-
fore detected, induces symptoms treated by the drug of
study. Moreover, as patients seek medical advice for car-
diac problems they are also subjected to a more careful
physical examination and a tumor may therefore be de-
tected and diagnosed soon after the start of treatment for
cardiac disease, thus leading to the false impression that
the drug induced the cancer. This can be avoided by in-
troducing lag times in the analysis. However in view of
the mostly unknown time course for the occurrence and
initial progression of solid tumors before they become
detected, the lag time applied will be arbitrary chosen.
One year lag time did not have any impact on our figures
indicating that this effect has not corrupted the present-
ed results. Another potential confounding factor is the
use of other cardiac drugs in the digitoxin group. Most
likely, the use of drugs such as angiotensin converting
enzyme (ACE) inhibitors, calcium antagonists and war-
farin is higher in the digitoxin group than in the control
group. The use of ACE inhibitors and warfarin have been
associated with a decreased risk of cancer [22,23],
whereas the use of calcium antagonists has been associ-
ated with an increased risk of cancer in some studies, but
not in all [24]. Thus, use of these drugs might have affect-
ed the results in both directions. Unfortunately, informa-
tion on concomitant drug use was not available in the
database.
Chemotherapy, especially in the form of anthracyclines,
may induce cardiac congestion and thus subsequent use
of digitalis [25]. However, it seems that it is just a small
fraction of all patients on digitalis who has had the cardi-
ac disease as a result of chemotherapy, so this should not
have corrupted our figures (Table 2), but still it will coun-
teract the detection of an eventual anticancer effect of
digitoxin to some extent in the analysis.
Based on theoretical assumptions it may be that the can-
cer incidence is not dramatically changed in patients on
digitalis, but that the survival nevertheless could be af-BMC Cancer 2001, 1:11 http://www.biomedcentral.com/1471-2407/1/11
fected. Our material was not suited for survival analyses
due the high age of the patients and the correspondingly
high mortality due to cardiac disease. Cancer patients are
also prone to get their cancer diagnosis on the death cer-
tificate, even if other conditions are the direct cause of
death. To make a fair analysis with focus on survival
time, autopsy data for most of the patients would be re-
quired [26], and such data were not available
Conclusion
It is evident from the present study that too many dis-
turbing factors exist in a population with serious cardiac
disease for making proper examination of possible anti-
cancer effects of cardiac glycosides. However, our study
gives some support to data from previous studies indi-
cating a higher incidence of cancer detected in patients
treated with digitalis, but this association should be as-
cribed to underlying factors inducing and/or promoting
both cancer and cardiovascular disease and not the actu-
al use of digitalis.
The possible role for cardiac glycosides in cancer treat-
ment has to be evaluated in prospective clinical studies
with cardiac glycosides as primary anticancer agents.
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